Males or females (willing to use accepted methods of contraception during the course of the study) in the age group of 18-65 yrs

Established CLI in the study limb, clinically and hemodynamically confirmed as per Rutherford- III-5

Patients in Rutherford- III-6 if gangrene extending maximally up to the head of metatarsal but limited to toes (Patients with wet gangrene must undergo wound debridement / amputation before screening)

Patients having infrapopliteal occlusive disease with rest pain and ischemic ulcer/necrosis, who are not eligible for or have failed traditional revascularization treatment as per the investigators judgment (No option patients)

Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent and video consent, abide by the study requirements, and agree to return for required follow-up visits

Exclusion Criteria:

Patients with CLI indicated for major amputation during screening

Atherosclerotic PAD

Ulcers with exposure of tendon and/bone in the shin region

Previous above transmetatarsal amputation in study limb

Any Lumbar sympathectomy procedure performed less than 90 days prior to the screening

Patients with gait disturbance for reasons other than CLI

Diagnosis of diabetes mellitus (type 1 or type 2)

Patients having left ventricular ejection fraction < 35%

Patients suffering from clinically relevant peripheral neuropathy

History of Stroke or myocardial infarction

Patients who are contraindicated for MRA

Patients with deep vein thrombosis in any limb

Patients who have clinically serious and/or unstable inter-current infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy

Documented terminal illness or cancer or any concomitant disease process with a life expectancy of <1 year

Patients already enrolled in another investigational drug trial or completed within 3 months or those who have participated in any stem cell clinical trial

Patient with known hypersensitivity to the constituents of the IMP - dimethyl sulfoxide (DMSO) or human serum albumin (HSA)